Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00062855 · ClinicalTrials.gov registry record · Phase 1

Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma

A Phase 1 study of Neuroblastoma, sponsored by Baylor College of Medicine.

Completed
Registry status
Phase 1
Development phase
9
Enrollment target
1
Study location

NCT00062855: Completed Phase 1 study of Neuroblastoma, sponsored by Baylor College of Medicine.

NCT00062855 is a Phase 1 study of Neuroblastoma that has completed, run by Baylor College of Medicine. The registered enrollment target is 9 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00062855, a Phase 1 study of Neuroblastoma, has completed, sponsored by Baylor College of Medicine.

COMPLETED
Registry status
Phase 1
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

This research study is designed to determine the safety and dosage of special cells that may make a patients own immune system fight the cancer. To do this we will put two special genes into cancer cells taken from the patients body. The genes we put in make the cancer cells produce lymphotactin, a natural substance that attracts immune system cells to the cancer, and IL-2 a natural substance that may help the immune system kill cancer cells. Some of these cells will then be put back in the patient's body. Studies of cancers in animals and in cancer cells that are grown in laboratories suggest that substances like lymphotactin and IL-2 help the body kill cancer cells. A treatment similar to this has been used in ten children previously and similar treatments are being used in adults with other cancers. The purpose of this study is to learn the side effects and safe 'dosage' of these special cells.

Conditions Studied

Neuroblastoma

Interventions

  • PROCEDURE Skin Biopsy
  • GENETIC Gene Modified Neuroblastoma Cells

Study Locations (1)

Texas

  • Texas Children's Hospital - Houston

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 1997-11
Est. Completion 2006-03
Phase Phase 1
Baylor College of Medicine

616 total trials

What the finished NCT00062855 record still lists

NCT00062855 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Neuroblastoma appearing as the primary indexed condition, and to 2 interventions - of which Skin Biopsy is the first listed.

NCT00062855 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT00062855 about?

NCT00062855 is a clinical study titled "Using Gene Modified Neuroblastoma Cells for the Treatment of Relapsed/Refractory Neuroblastoma". This research study is designed to determine the safety and dosage of special cells that may make a patients own immune system fight the cancer. To do this we will put two special genes into cancer cells taken from the patients body. The genes we put in make the cancer cells produce lymphotactin, a ...

What is the current status of trial NCT00062855?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 1997-11. Estimated completion is 2006-03.

What conditions does trial NCT00062855 study?

This clinical trial studies the following conditions: Neuroblastoma.

What interventions are being tested in trial NCT00062855?

The interventions under investigation include: Skin Biopsy (PROCEDURE), Gene Modified Neuroblastoma Cells (GENETIC).

Who is sponsoring clinical trial NCT00062855?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00062855 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neuroblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00062855's enrollment target sits among peer trials

9 91st of 94 higher than 3 of 94 other Neuroblastoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00062855, the US trial registry maintained by the National Library of Medicine. NCT00062855 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.